These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17460703)

  • 1. Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab.
    Royer B; Vaida I; Etienne A; Garidi R; Damaj G; Marolleau JP
    Leukemia; 2007 Aug; 21(8):1841-2; author reply 1842-3. PubMed ID: 17460703
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
    Karlsson C; Hansson L; Celsing F; Lundin J
    Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.
    Laurenti L; Tarnani M; Efremov DG; Chiusolo P; De Padua L; Sica S; Leone G
    Leukemia; 2007 Aug; 21(8):1819-21; author reply 1821. PubMed ID: 17443222
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
    Osterborg A; Karlsson C; Lundin J
    Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.
    Lundin J; Karlsson C; Celsing F
    Med Oncol; 2006; 23(1):137-9. PubMed ID: 16645240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab.
    d'Arena G; de Filippi R; Pinto A
    Leuk Lymphoma; 2007 Mar; 48(3):625-7. PubMed ID: 17454610
    [No Abstract]   [Full Text] [Related]  

  • 7. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
    Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
    Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
    [No Abstract]   [Full Text] [Related]  

  • 8. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
    Lee D
    Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.
    Rodon P; Breton P; Courouble G
    Eur J Haematol; 2003 May; 70(5):319-21. PubMed ID: 12694169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
    Smith JA
    Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
    Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
    Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
    [No Abstract]   [Full Text] [Related]  

  • 12. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
    Pitini V; Arrigo C; Barresi G
    Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab.
    Ammatuna E; Marino C; Mitra ME; Calvaruso G; Iannitto E
    Eur J Haematol; 2004 Sep; 73(3):225-6. PubMed ID: 15287923
    [No Abstract]   [Full Text] [Related]  

  • 15. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
    Oberoi SS; Abou Jawde RM
    J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L; Tarnani M; Innocenti I; Savino G; Battendieri R; Larocca LM; Chiusolo P; Sorà F; Sica S; Efremov D; Leone G
    J Clin Oncol; 2008 Nov; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract]   [Full Text] [Related]  

  • 17. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I; Grossbard ML
    Clin Lymphoma; 2004 Mar; 4(4):228-9. PubMed ID: 15072614
    [No Abstract]   [Full Text] [Related]  

  • 18. Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by Rituximab.
    Shvidel L; Shtalrid M; Berrebi A
    Leuk Lymphoma; 2004 Jul; 45(7):1493-4. PubMed ID: 15359657
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
    Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P
    Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216
    [No Abstract]   [Full Text] [Related]  

  • 20. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
    Keating M; Hallek M
    Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.